Alexander R. Menter, MD
Recent clinical trial results are starting to redefine the treatment paradigm for patients with early-stage non–small cell lung cancer (NSCLC), explained Alexander R. Menter, MD.
“There are...studies that are showing improved survival rates in patients with lung cancer, and we need to be listening to those,” said Menter, an oncologist at Kaiser Permanente.
Data from the 2018 ASCO Annual Meeting showed that the use of lymph node collection kits during lung resection resulted in improved survival rates compared with centers where they were not available. In a prospective, staggered-implementation study, 1171 patients underwent resection in 11 participating hospitals. The 3-year overall survival (OS) rates at a median follow-up of 20 months were 80% and 73% in kit and non-kit cases, respectively (P
... to read the full story